Merck anesthesia-reversal agent faces new delay
March 15 (Reuters) - The U.S. Food and Drug Administration will not complete its review of Merck & Co's experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three month delay, the drugmaker said.
Merck acquired the product, called sugammadex, through its merger in 2009 with Schering-Plough Corp. It has faced numerous previous regulatory delays, but is deemed by many industry analysts and doctors as one of the biggest potential breakthroughs in anesthesia in recent decades.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky in Germany after pardon |
- Target cyber breach hits 40 million payment cards at holiday peak |
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter